MedPath

Neuraxial Labor Analgesia and the Incidence of Postpartum Depression

Completed
Conditions
Parturition
Depression, Postpartum
Analgesia, Obstetrical
Registration Number
NCT02823418
Lead Sponsor
Peking University First Hospital
Brief Summary

Postpartum depression (PPD) affects approximately 15% of women during the first year after giving birth, and is common across cultures. The etiology of postpartum depression is not totally clear. The severe pain experienced during childbirth was reported to be associated with the development of postpartum depression. The purpose of the present study is to evaluate whether use of neuraxial labor analgesia can reduce the incidence of postpartum depression.

Detailed Description

Postpartum depression (PPD) affects approximately 15% of women during the first year after giving birth, and is common across cultures. In postpartum Chinese women, the reported incidence ranged from 6.5% to 29.5%.

The etiology of postpartum depression is not totally clear. Identified risk factors include previous maternal blues, unplanned pregnancy, lack of marital or social support, and previous psychiatric illnesses. Furthermore, the severe pain experienced during childbirth was reported to be associated with the occurrence of postpartum depression.

A recent study of the investigators found that use of epidural analgesia during labor was associated with decreased risk of postpartum depression. However, several limitations existed in that study and further evidence is needed to reconfirm the finding. The purpose of the present study is to reevaluate whether use of neuraxial labor analgesia can reduce the incidence of postpartum depression.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
599
Inclusion Criteria
  1. Primiparae between 18 and 34 years of age with term single cephalic pregnancy;
  2. Admitted to the delivery room during daytime working hours (from 8 am to 5 pm).
  3. Preparing to deliver vaginally.
Exclusion Criteria
  1. History of psychiatric disease (indicate those that are diagnosed before or during pregnancy by psychiatrists);
  2. Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy.
  3. Other reasons that are considered unsuitable for study participation.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of postpartum depressionAt 42 days after delivery

Postpartum depression will be defined by a score of 10 or more on the Edinburgh Postnatal Depression Scale.

Secondary Outcome Measures
NameTimeMethod
Status of baby feedingAt 24 hours and 42 days after delivery

The mode of baby feeding include breast feeding, mixed feeding, and formula feeding.

Persistent painAt 42 days after delivery

Persistence pain is defined as a NRS pain score ≥1 that persisted since childbirth.

Neonatal Apgar scoreAt 1 and 5 minutes after delivery

The Apgar score ranges from 0 to 10, with higher score indicating a better outcome. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low and cause for immediate resuscitative efforts.

The mode of deliveryAt the time of delivery

The mode of delivery includes spontaneous delivery, instrumental delivery, and Caesarean delivery.

Severity of painAt 24 hours and 42 days after delivery

Severity of pain is evaluated with Numeric Rating Scale (NRS), where 0 indicates no pain and 10 the most severe pain.

Persistent pain affecting daily lifeAt 42 days after delivery

One of the following activities (including walking, mood, sleep or concentration) is affected by persistent pain, as judged by parturients themselves.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.